Christoph Lengauer
Partner @ Third Rock Ventures
Boston, United States
Christoph Lengauer is a Series A investor at Third Rock Ventures in Boston focused on Medical and Health Care. Christoph is Co-Founder and CSO at Curie.Bio. Curie.Bio is a founder-focused seed-stage venture firm combined with an industry-grade therapeutics accelerator focused on one thing: helping entrepreneurial founders launch viable therapeutics companies. Curie.Bio does this by giving founders access to a team of the world’s best drug hunters and drugmakers, seed capital, and best-of-breed services - everything a founder needs to get from concept to a compelling dataset that enables an awesome Series A financing. And we do this at scale for 40+ companies / year.Christoph was previously a Venture Partner at Third Rock Ventures, where he helped discover, launch, and build companies based on bold ideas that meet at the intersection of science, strategy, business, and medicine. He was also previously President of Celsius Therapeutics, a startup that develops medicines by understanding the ecosystem of cells using single-cell genomics.In fall of 2015, Christoph was appointed CEO by the German Ministry for Economy to lead the buildout of the German Accelerator Life Sciences (GALS) in Cambridge, MA and Berlin, Germany. GALS provides high-end consulting to emerging German life-science companies and supports them with introducing their products to the US market. In 2017, Christoph founded Advise.Connect.Inspire, which provides similar services to companies across all of Europe.Christoph was also formerly Executive Vice President at Blueprint Medicines (BPMC), where he was the founding CSO and has been leading the clinical progression of BLU-285 until its recent breakthrough therapy designation granted by the FDA for the treatment of patients with unresectable or metastatic PDGFRA D842V mutated gastrointestinal stromal tumors.Christoph has a proven record in drug discovery and contributed to more than 25 drugs that reached human clinical trials as well as four approved lifesaving medicines (Kisqali, Odomzo, Zaltrap, Jevtana). Christoph also worked for approximately ten years at Novartis and as Global Head of Oncology Drug Discovery and Preclinical Development at Sanofi.Prior to joining the pharma/biotech industry, Christoph was an associate professor at the Sidney Kimmel Comprehensive Cancer Center at the Johns Hopkins University School of Medicine in Baltimore, MD. Christoph discovered that all cancers are genetically unstable. While co-leading the Vogelstein lab for about a decade, he was involved in the identification of several cancer-driver genes, including BRAF and PIK3CA.Christoph holds adjunct associate professor positions at Johns Hopkins University and Harvard University. A strong and outspoken advocate of patients’ rights, he is featured in the New York Times bestseller and HBO movie, The Immortal Life of Henrietta Lacks.
- Total investments:
- 1
- Last investment:
- Lead investor:
- 100%
Last updated:
For AI agents: llms.txt
Industries Christoph Lengauer invests in
Stages Christoph Lengauer invests in
Countries Christoph Lengauer invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Medical 1 (100%)
- Health Care 1 (100%)
- Biotechnology 1 (100%)
- Health Diagnostics 1 (100%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Thrive is a healthcare company focused on saving lives by making earlier detection of cancer a routine part of medical care. It develops CancerSEEK, a liquid biopsy test that is designed to detect many cancers at earlier stages of the disease. CancerSEEK will serve as the core of Thrive’s integrated cancer information offering.The company waslaunched in 2019 by Third Rock Ventures, with funding from additional investors Section 32, Casdin Capital, Biomatics Capital, BlueCross BlueShield Venture Partners, The Invus Group, Camden Partners Nexus, Cowin Venture, Exact Sciences, and Gamma3. | $110M / Series A / May 30, 2019 |
Co-Investors
About Third Rock Ventures
Third Rock Ventures invests in transformational life science companies that show high growth potential and are well-positioned to make a difference in the marketplace. Third Rock Ventures believes in the companies we start and makes significant initial investments, which are frequently supplemented by strategic collaborations, to help our firmsprogress in life-changing medicines, technologies, and diagnostics.
Third Rock Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Cary Pfeffer
Partner
|
|||
|
Jeff Tong
Partner
|
|||
Jigar Raythatha
Partner
|
|||
Mark Levin
Partner
|
|||
Reid Huber
Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Christoph Lengauer invest in?
Christoph Lengauer invests primarily in Medical, Health Care and Biotechnology startups, most often at Series A stage. Most of the 1 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Christoph Lengauer?
Public channels for Christoph Lengauer include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Christoph Lengauer last invest?
The most recent investment recorded for Christoph Lengauer closed in May 2019. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
